Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience

Abstract Background The optimal treatment for recurrent high-grade gliomas (rHGGs) remains uncertain. This study aimed to investigate the efficacy and safety of hypofractionated stereotactic radiosurgery (HSRS) as a first-line salvage in-field recurrence gliomas. Methods Between January 2016 October 2019, 70 patients with rHGG who underwent HSRS were retrospectively analysed. primary endpoint was overall survival (OS), secondary endpoints included both progression-free (PFS) adverse events, which assessed according Common Toxicity Criteria Adverse Events (CTCAE) version 5. prognostic value key clinical features (age, performance status, planning target volume, dose, use bevacizumab) evaluated. Results A total in study. Forty male 30 female. Forty-nine had an initial diagnosis glioblastoma (GBM), rest (21) confirmed be WHO grade 3 median volume (PTV) 16.68 cm (0.81–121.96 ). prescribed dose 24 Gy (12–30 Gy) 4 fractions (2–6 fractions). baseline Karnofsky Performance Status (KPS) (40–90). With follow-up 12.1 months, after 17.6 months (19.5 14.6 gliomas, respectively; p = .039). No or higher toxicities recorded. Multivariate analysis showed that concurrent bevacizumab KPS > favourable factors HGG. Conclusions Salvage outcome acceptable toxicity rHGG. prospective phase II (NCT04197492) is ongoing further